"How to manage loss of response to anti-TNF in Crohn's disease? ".
Despite the fact that anti-TNF alpha antibodies are well-tolerated and highly effective in Crohn's disease 25% to 40% of patients who initially benefited from treatment are developing intolerable adverse events or are loosing their response during maintenance therapy. The molecular mechanisms of loss of response are not fully understood, but clinician face this clinical problem. The aim of this paper is to review the clinical strategies to face anti-TNF alpha antibodies in Crohn' disease.
Reinisch
Walter
W
Universitätsklinik Innere Medizin III, Abteilung Gastroenterologie und Hepatologie, Waehringer Guertel 18-20, A-1090 Vienna, Austria. walter.reinisch@meduniwien.ac.at
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha